Skip to main content
Clinical Trials/NCT02922036
NCT02922036Active, not recruitingNot Applicable

Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders, Previously Untreatable and High Risk Upgrade Patients (SOLVE CRT)

EBR Systems, Inc.127 sites in 2 countries300 target enrollmentStarted: January 17, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
300
Locations
127
Primary Endpoint
Primary Efficacy 1

Study Overview

Brief Summary

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

Detailed Description

The WiSE-CRT System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
None

Masking Description

One part of the study was randomized. The final part of the study was single-arm, open label.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Primary Efficacy 1

Time Frame: 6 Months

Mean relative % change in Left Ventricular End Systolic Volume (LVESV) baseline to 6 Months.

Primary Safety

Time Frame: 6 Months

Freedom from Procedure and Device System related Type 1 Complications

Secondary Outcomes

  • Secondary Efficacy 2(6 Months)
  • Secondary Efficacy 5(6 months)
  • Secondary Efficacy 3(6 months)
  • Secondary Efficacy 1(6 Months)
  • Secondary Efficacy 4(6 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (127)

Loading locations...

Similar Trials